This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Sign in
Sign In or Register
Sign out

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Explore Content

Information on how to access prescribing information and adverse event reporting can be found at the bottom of the page.

Our Commitment to Anti-Infectives

About AMR

Antimicrobial Resistance (AMR) occurs when pathogens change and find ways to resist the effects of antimicrobial agents. The pathogens survive, grow and spread their resistance. This process of adaptation leads to AMR.1

Antimicrobial resistance, particualrly in Gram-negative bacteria, is widely recognised as one of the biggest threats to global health today, with the potential to affect anyone, of any age, in any country.2,3,4

Globally, AMR causes 700,000 deaths annually. Without actions by governments, industry and society, AMR is expected to casue 10 million deaths by 2050 - more than currently die from cancer.1

How Pfizer is helping address AMR

Pfizer has one of the industry’s largest and most diverse portfolios of antimicrobials and is proud to be taking a lead in the fight to tackle AMR.5 We are deeply committed to working closely with the infectious disease community to address AMR6 through5:

Active stewardship: to ensure patients receive the correct antibiotic, according to independent guidelines, only if needed and for the right duration7
Innovative surveillance tools: to help physicians better understand current resistance patterns
Global policy leadership: to facilitate antibiotic development and proper use
Diverse portfolio: medicines and vaccines to treat and help prevent serious infections around the world
Manufacturing: responsible practices that do not harm human health or the environment

AMR Action Fund

Pfizer have pledged US $100 million to the Antimicrobial Resistance (AMR) Action Fund which launched in July 2020, to help address the significant global public health need for new antibiotics due to the rapid rise of antibiotic resistant infections.

The AMR Action Fund is a ground-breaking collaboration among more than 20 biopharmaceutical companies, philanthropies, development banks and multilateral organisations to re-invigorate and accelerate antiobiotic development.8

References:
  1. Review on Antimicrobial Resistance. Tackling drug-resistant infections globally: final report and recommendations. May 2016. Available at: https://amr-review.org/sites/default/files/160525_Final%20paper_with%20cover.pdf [Last Accessed July 2020]​
  2. World Health Organization. WHO’s first global report on antibiotic resistance reveals serious, worldwide threat to public health. April 30 2014. Available at: http://www.who.int/mediacentre/news/releases/2014/amr-report/en/​ [Last accessed July 2020] ​
  3. World Health Organization. Antibiotic Resistance Factsheet. February 2018. Available at: https://www.who.int/news-room/fact-sheets/detail/antibiotic-resistance [Last accessed July 2020]​
  4. Vasoo S et al. Emerging issues in gram-negative bacterial resistance: an update for the practicing clinician. Mayo Clinic Proc. 2015;90:395-403.​
  5. Pfizer Annual Review 2018. Available at: https://www.pfizer.com/sites/default/files/investors/financial_reports/annual_reports/2018/assets/pdf/pfizer-2018-annual-review.pdf [Last accessed July 2020]​
  6. Pfizer Policy position in antimicrobial resistance (AMR) August 2017. Available at:​ https://pfe-pfizercom-d8-prod.s3.amazonaws.com/about/Policy-Position-on-Antimicrobial-Resistance-8-17-17.pdf [Last accessed July 2020]​
  7. Davey P, Marwick CA, Scott CL, et al. Interventions to improve antibiotic prescribing practices for hospital inpatients. Cochrane Database Syst Rev. 2017;2:Cd003543.​
  8. Pfizer pledges $100 million to new industry fund to help fight growing threat of antimicrobial resistance. Available at: https://www.pfizer.co.uk/pfizer-pledges-100-million-new-industry-fund-help-fight-growing-threat-antimicrobial-resistance [Last accessed July 2020]​
PP-AIP-GBR-0801. September 2021

See our heritage in antibacterials

See now

See our heritage in antifungals

See now

Educational Resources

We have a variety of educational resources aimed at supporting Healthcare Professsionals looking to enhance their knowledge of AMR and Stewardship.

Access resources

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in Google Play or Apple App Store

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-3863. November 2021

Yes

No

OK, We will need you to sign in before we can determine if you are aligned with a Pfizer promotional colleague.This is an interstitial message to prompt a HCP before they login.

If you have already registered with pfizerpro.co.uk and select ‘yes’, you will be directed to the sign-in page where you will be required to enter your username and password.

Would you like to register or sign in now?